Friday, March 08, 2019
Undisclosed pharmaceutical technology company ReForm Biologics, which develops innovative biopharmaceutical manufacturing methods to improve drug delivery / manufacturing, today announced that Astellas Pharma Inc. TSE: 4503) (hereinafter referred to as "Astellas") and collaboration aimed at reducing the viscosity of Astellas' biopharmaceutical pipeline program at the clinical stage. Reform's technology platform brings innovation to the preparation of biopharmaceuticals, achieves alternative dosing regimens, enhances production efficiency, and extends the product's life cycle.
In accordance with the terms of the agreement, Astellas will provide funding for this collaboration and will be conducted at the facility of ReForm Biologics in Uuban, Massachusetts.
Dr. John M. Sorvillo, Chief Executive Officer (CEO) of ReForm Biologics, says: "It is exciting for us that we can start collaborating with the world-leading Astellas by transforming innovative scientific results into values ??for patients.We are pleased that the team of Astellas Innovation Management has concluded this contract We appreciate the efforts that led to this collaboration, which will prove that the new preparation technology can optimize the dosing regimen and support lifecycle management with the drug development program.We work with Astellas to develop this clinical I would like to support the development of stage assets. "